Aptevo to Showcase Multispecific Platform at SITC 2026 Annual Meeting
Key Highlights
- ➤Aptevo to present its CD40-directed multispecific portfolio at SITC 2026
- ➤Presentation targets localized CD40 agonism to overcome tumor immunosuppression
- ➤Aptevo combines tumor targeting with CD40 and T cell activation
- ➤SITC presentation scheduled November 4-8, 2026, in Phoenix
Expert Statements
Mary Janatpour, Senior Vice President and Chief Scientific Officer of Aptevo
“We're pleased to share progress from an important area of focus for Aptevo as we continue to expand the capabilities of our multispecific platform.”
Mary Janatpour, Senior Vice President and Chief Scientific Officer of Aptevo
“Our multispecific technology is designed to bring complementary mechanisms together in a single molecule and create a deeper immune response within the tumor microenvironment.”
Mary Janatpour, Senior Vice President and Chief Scientific Officer of Aptevo
“By combining tumor targeting with localized CD40 and T cell activation, we believe we have an opportunity to engage both innate and adaptive immunity where it matters most - at the tumor - while seeking to limit systemic immune activation.”
Mary Janatpour, Senior Vice President and Chief Scientific Officer of Aptevo
“This work reflects the continued evolution of our platform and our strategy to build a next generation of multispecific therapies designed to address some of the most persistent challenges in solid tumors.”
SEATTLE, WA / ACCESS Newswire / October 14, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel bispecific and multispecific immunotherapies for the treatment of cancer, today announced that the Company will highlight its multispecific platform in a presentation at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, being held November 4-8, 2026, at the Phoenix Convention Center in Phoenix, Arizona.
Aptevo's presentation will feature its broader CD40-directed multispecific portfolio and the Company's approach to bringing together two critical arms of the immune system - innate and adaptive immunity - within the tumor microenvironment. Solid tumors can suppress or disrupt anti-tumor immune responses, limiting the ability of the immune system to recognize and effectively attack cancer. Aptevo's tumor-directed CD40-activating molecules also act on the cells that mediate tumor cell killing and are designed to help overcome that challenge by localizing immune activation to the tumor and promoting a more complete anti-tumor response.
Get started
Create a free account to read the full story.